Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378660 | 0.78 | POLB (0.50) | POLBMAPK1ATMKDM4EMAPT | |
| SCHEMBL3806194 | 0.78 | CYP3A4 (0.50) | POLBKDM4EMAPTTLR8HSD17B10 | |
| SCHEMBL1154415 | 0.76 | MAPK1 (0.48) | POLBMAPK1ATMKDM4EMAPT | |
| SCHEMBL31474375 | 0.76 | SLC9A1 (0.48) | KDM4EMAPTLMNATLR8HSD17B10 | |
| SCHEMBL28812584 | 0.76 | GRM2 (0.50) | POLBMAPK1ATMMAPTLMNA | |
| Water SCHEMBL3673310 | 0.76 | POLB (0.48) | POLBMAPK1ATMKDM4EMAPT | |
| SCHEMBL2113290 | 0.76 | MAPK1 (0.48) | POLBMAPK1ATMKDM4EMAPT | |
| SCHEMBL4635179 | 0.76 | SLC9A1 (0.48) | KDM4EMAPTLMNATLR8HSD17B10 | |
| SCHEMBL3282850 | 0.76 | GRM2 (0.50) | POLBMAPK1ATMMAPTLMNA | |
| SCHEMBL2670682 | 0.76 | POLB (0.48) | POLBMAPK1ATMKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 379 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115522238-B | Cyanide-free gold electroplating solution of sodium gold sulfite and electroplating process thereof | 深圳创智芯联科技股份有限公司 | 2023-04-21 | — | — | CN | claimed |
| CN-115522238-A | Cyanide-free gold plating solution of sodium gold sulfite and plating process thereof | 深圳创智芯联科技股份有限公司 | 2022-12-27 | — | — | CN | claimed |
| US-20150166537-A1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE | WOCKHARDT LTD. (IN) | 2015-06-18 | — | — | US | claimed |
| US-8969567-B2 | Nitrogen containing compounds and their use | WOCKHARDT LTD. (IN) | 2015-03-03 | — | — | US | claimed |
| US-20140296526-A1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE | WOCKHARDT LIMITED (IN) | 2014-10-02 | — | — | US | claimed |
| US-5015555-A | Adhesion, flexibility | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-05-14 | — | — | US | claimed |
| JP-55149393-A | — | — | None | — | — | JP | disclosed |
| US-6409771-B1 | — | — | None | — | — | US | disclosed |
| CN-112469707-B | Preventive or therapeutic agent for spinal muscular atrophy | 利伯纳生物科学株式会社 | 2024-06-21 | — | — | CN | disclosed |
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | REBORNA BIOSCIENCES, INC. (JP) | 2024-06-18 | — | — | US | disclosed |
| EP-3444336-B1 | CLEANING AGENT | PROCTER & GAMBLE (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-117756834-A | Synthesis method of 2- (aminocarbonylmethyl) phenylboronic acid pinacol ester | 大连双硼医药化工有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20240092784-A1 | CONDENSED HETEROCYCLIC COMPOUND | NISSAN CHEMICAL CORPORATION (JP) | 2024-03-21 | — | — | US | disclosed |
| EP-0242896-A2 | Novel intermediates useful in the production of gem-diaminoalkane derived sweeteners | CUMBERLAND PACKING CORPORATION (US) | 1987-10-28 | — | — | EP | disclosed |
| US-4636396-A | Foodstuff with L-aminodicarboxylic acid gem-diamines | GENERAL FOODS CORPORATION (US) | 1987-01-13 | — | — | US | disclosed |
| US-4619782-A | L-aminodicarboxylic acid gem-diamines | GENERAL FOODS CORPORATION (US) | 1986-10-28 | — | — | US | disclosed |
| US-4571345-A | 1,1-Diaminoalkane derived sweeteners | CUMBERLAND PACKING CORP. (US) | 1986-02-18 | — | — | US | disclosed |
| EP-0128654-A2 | Gem-diaminoalkane derived sweeteners | CUMBERLAND PACKING CORPORATION (US) | 1984-12-19 | — | — | EP | disclosed |
| US-4465625-A | ANALGESICS | RICHTER GEDEON VEGYESZETI GYAR (HU) | 1984-08-14 | — | — | US | disclosed |
| JP-S55149393-A | LUBRICATING AND RUST-PROOFING AGENT FOR COPPER OR COPPER ALLOY | TATSUTA ELECTRIC WIRE & CABLE CO LTD | 1980-11-20 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | SMN1; SMN2, HDAC5, PUM1 | POLB 1451/4885MAPK1 625/4885ATM 2434/4885 |
| US-20140296526-A1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE | NOS2, NOS1, NOS3 | POLB 770/4885MAPK1 1618/4885ATM 2043/4885 |
| US-20150166537-A1 | NITROGEN CONTAINING COMPOUNDS AND THEIR USE | NOS2, NOS1, NOS3 | POLB 770/4885MAPK1 1618/4885ATM 2043/4885 |
| US-20240092784-A1 | CONDENSED HETEROCYCLIC COMPOUND | SPR, QDPR, SUCNR1 | POLB 1284/4885MAPK1 2429/4885ATM 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.